Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.
Authors:
- F R AppelbaumFAF R Appelbaum
- R HillRHR Hill
- L D FisherLFL D Fisher
- C L BigelowCBC L Bigelow
- J E SandersJSJ E Sanders
- K M SullivanKSK M Sullivan
- W I BensingerWBW I Bensinger
- R P WitherspoonRWR P Witherspoon
- R StorbRSR Storb
- 1 April 1990
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 8 (4) , 638-647
Abstract
Between October 1979 and January 1988, 101 patients with malignant lymphoma who failed initial induction treatment or relapsed received high-dose combination chemotherapy or chemoradiotherapy followed by infusion of autologous bone marrow. Twenty-eight of the 101 patients survive, 18 of whom are disease-free for a median of 26 (range, 12 to 66) months. The 5-year actuarial probabilities of survival, event-free survival (EFS), and relapse from transplantation were 20%, 11%, and 84%, respectively. Multivariate analysis showed that the likelihood of EFS was decreased among patients transplanted with a Karnofsky score of less than 80%. Recurrent lymphoma after transplant was the most important cause of treatment failure with 36 of 62 relapses occurring within 100 days from marrow infusion. Early, but not late relapse, was more frequent in patients transplanted for advanced lymphoma, and both early and late relapses were increased among patients with impaired pretransplant clinical performance or high-grade histology of lymphoma. Ten patients who relapsed post-transplant are alive, seven in remission. Further improvement of these results will require earlier transplantation, improved preparative regimens, or early posttransplant therapy.Keywords
This publication has 8 references indexed in Scilit:
- Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma.Journal of Clinical Oncology, 1989
- Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.Journal of Clinical Oncology, 1989
- USE OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN AUTOLOGOUS MARROW TRANSPLANTATION FOR LYMPHOID MALIGNANCIES1988
- Chemotherapy in patients who fail radiotherapy for diffuse aggressive non-hodgkin's lymphomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1987
- Prolonged Disease-Free Survival after Autologous Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma with a Poor PrognosisNew England Journal of Medicine, 1987
- High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphomaEuropean Journal of Cancer and Clinical Oncology, 1986
- Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's DiseaseAnnals of Internal Medicine, 1982
- IMVP-16 - AN EFFECTIVE REGIMEN FOR PATIENTS WITH LYMPHOMA WHO HAVE RELAPSED AFTER INITIAL COMBINATION CHEMOTHERAPY1982